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Therapeutic ultrasound is a noninvasive technique, which is well tolerated by horses, does not need
sedation, and can easily be performed in a routine clinical setting. Twenty-three client-owned sport
horses were recruited at Clinica Equina San Biagio and included in this case study. Treatment of the
injured suspensory ligament apparatus was administered using an EQ Pro, low-frequency therapeutic
unit (38 kHz). The noninvasive treatment consisted of massaging the injured area in combination with a
traditional ultrasound gel while maintaining the head of the device in direct contact with the injured
area. The results indicate that 20 of the 23 horses in this study beneﬁtted from EQ Pro treatment and,
following a routine rehabilitation program, returned to competition status: a success rate of 87%.
Furthermore, treatment duration was 3.3 ± 0.4 weeks on average, with a healthy outcome as assessed by
ultrasound at 6.8 ± 1.9 weeks. Among the 23 horses in this study, 65% of them beneﬁtted from EQ Pro
treatment of a duration of just 3.3 weeks. It is concluded that EQ Pro therapy is a promising and
effective form of treatment for horses with suspensory ligament injury. It is furthermore rapid and easy
to use in the Equine Veterinary Clinic setting and does not require sedation. Future studies should now
focus on the mechanisms by which this new treatment activates the healing process of the suspensory
ligaments of injured horses.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lameness remains the main cause of loss of performance in the
equine industry, and suspensory ligament (SL) issues are one of the
most common causes of lameness in horses [1e4]. Injury to the
main SLs or to either one or even both of the SL branches isof charge by the company for
as received from EQ Pro nor
oved by the management and
Argenta (FE), Italy. There was
ng equipment used complied
e in its nature. The study was
Helsinki Declaration (https://
inki-ethical-principles-for-
o protect to owners names,
o conﬂicts of interest.
ægevej, Frederiksberg C 1871,
gio.it (U. Carrozzo).
Inc. This is an open access article ucommon in all types of athletic horses [5,6]. Indeed, injury to ﬂexor
tendons or the SLs has been reported to account for up to 46% of all
limb injuries in performance and racehorses [1,2,7]. Moreover, it
has been stated that “lameness often has been slow to resolve
(2e3 months) with a total duration of convalescence ranging from
3 to 6 months” [8].
The main function of the SL is to prevent overextension of the
fetlock joints during the weight-bearing phase of a horse's stride.
Injuries to the SL typically arise when the load placed on them
exceeds their combined strength. For the equine SL, this most often
occurs at the middle of the stance phase of the stride [6].
Following an injury to a ligament, the healing process follows a
very predictable sequence of inﬂammation, proliferation or repair,
and remodeling [9]. However, an underlying problem in terms of
healing is the fact that ligaments are relatively poorly vascularized,
and a good vascular system is required to facilitate cell inﬁltration
and the supply of growth factors needed for full tissue healing [10].
It is for this reason that the use of recombinant proteins and
gene therapy has been looked at in terms of a promising approach
to treatment of such injuries, based on its success in muscle dis-
orders in humans [11]. Indeed, as an approach, it has been shown tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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perﬁcial digital ﬂexor tendon [9]. Other forms of treatment include
platelet-rich plasma (PRP) [12], autologous bone marrow aspirate
[13], and extracorporeal shockwave therapy [14]. Indeed, a com-
bination of both PRP and extracorporeal shockwave has recently
been proposed as a means of increasing the expression of impor-
tant growth factors in regions of soft tissue injury, thereby creating
a synergistic effect and hastening the healing process [14].
The use of low-frequency therapeutic ultrasound (US) to treat
equine conditions is as yet a new and evolving science. As a tech-
nique, therapeutic US is noninvasive and well tolerated by horses
without the need of sedation. Furthermore, it can be easily per-
formed in a routine clinical setting. EQ Pro low-frequency thera-
peutic US generates intense acoustic effects, thermal effects, and
mechanical vibration. The acoustic effects are cavitation, acoustical
streaming, and microstreaming. Thermal effects are induced by EQ
Pro continuous emission transducers, heating deep tissues with a
minimal increase in temperature of the superﬁcial tissues. Me-
chanical vibration is induced by EQ Pro pulsed emission trans-
ducers: the intermittence of oneoff cycles allows heat dissipation
by blood circulation and creates a therapeutic mechanical
vibration.
The aim of this case study has therefore been to examine the
efﬁcacy of low-frequency US and present the response to treatment
in combination with a careful exercise program in 23 horses.2. Materials and Methods
2.1. Ethics
There were no ethical issues associated with this study. The
equipment used complied with both Conformite Europeenne and
Federal Communications Commission regulations and was nonin-
vasive in its nature. The study was carried out according to the
guidelines laid out in the Helsinki Declaration (https://www.wma.
net/policies-post/wma-declaration-of-helsinki-ethical-principles-
for-medical-research-involving-human-subjects/), and care was
taken not to unduly stress the horses. The data collected were from
privately owned horses over a period of 24months (January 2016 to
December 2017), and as such, this work should be seen as a
retrospective study.2.2. Animals
Animals were recruited through the Clinica Equina San Biagio.
The following criteria were adopted
Inclusion criteria are as follows: (1) unilateral lameness; (2)
swollen or thickened SL or its branch(es); (3) positive diagnostic
analgesia; and (4) ultrasonographic evidence of acute or chronic,
focal or diffuse simple or complicated lesion(s) of SLs.
Exclusion criteria are as follows: (1) lameness complicated by
multiple injuries that involved other structures, (2) horses that had
developed drop off of the fetlock with consequent elongation of the
SL, and (3) dystrophic mineralization of the SL and/or of the per-
iligamentous ﬁbrous tissue.
Twenty-three horses met both the inclusion and exclusion
criteria. The population consisted of 14 geldings, 7 mares, and 2
stallions, with a breakdown as follows: one polish-warmblood,
three Hanoverians, six Holsteiners, three KWPN Royal Dutch
Sports horses, one Oldenburg, four Sella Italiano, two English
Thoroughbreds, one Belgian Warmblood, one Selle Français, and
one Quarter Horse. The average (mean ± standard deviation)
weight and age were 584 ± 54 kg and 11 ± 3 years, respectively.2.3. Study
The injuries outlined in this study all occurred naturally, which
adds a degree of difference in terms of their entity and their
severity. The horse population also differed greatly in terms of age
and breed. This study was also subject to logistics issues in terms of
treatment between individual horses (three treatment protocols
were adopted: Protocol 1: acute cases; Protocol 2: subacute cases;
Protocol 3: chronic cases: for details see below), with some horses
skipping some treatment sessions or indeed ﬁnishing therapy
earlier than had initially been planned. All these variables should be
taken into account when considering the noticeably different out-
comes of this study with regard to the time spent to heal lesions as
well as the time spent before a return to regular sport activities.
2.4. Assessment
Each horse was subjected to a complete physical and lameness
evaluation. Any palpable abnormalities (thickening, swelling, and
so forth) were recorded. The horses were initially evaluated by an
experienced lameness clinician (U.C. and M.T.) while moving at a
walk and a trot in a straight line and in a circle, both on a hard and a
soft surface.
Diagnostic analgesia was performed to conﬁrm the source of
pain. Horses with lesion of suspensory branch were positive (>80%
improvement of lameness) to low 4-point block (3 cc mepivacaine
2% around palmar/plantar metacarpal/tarsal nerves and 4 cc
around palmar/plantar nerves).
Horses with lesion of the origin of SL were blocked with small
amount of anesthetic solution (3 cc mepivacaine 2%) directly
injected into the lesion or around tibial nerve (one horse) with US-
guided injection.
Thereafter, the SLs were examined using a diagnostic US unit
(Esaote Alpha diagnostic unit; Esaote SpA, Genoa, Italy; performed
by U.C. and M.T.) not only to locate the site of lameness but also to
assess the degree of the injury (for details see Table 1 and Fig. 1).
Clinical relevance of lesion(s) was evaluated and conﬁrmed by ul-
trasonographic examination usually complemented by a radio-
graphic examination to highlight osseous or joint abnormalities.
There was not a strict and consistent correlation between the
lameness score and the severity of lesions as evaluated by the US
images. An overall evaluation of the severity of an individual injury
was therefore taken using a combination of clinical records, diag-
nostic imaging, and patient indications.
Transverse and longitudinal sections of proximal, body, and
branches of SL were taken, and most representative images of the
lesion(s) were digitized using commercially available DICOM
viewer and analyzer software (Osirix MD, PIXMEO Sarl 2016);
cross-sectional areas (CSAs) were measured by manually tracing
the borders of the region of interest and automatically calculating
the area included; longitudinal sections were analyzed for ﬁber
alignment percentage and classiﬁed as poor (<50% ﬁbers aligned),
fair (¼50% ﬁbers aligned) and good (>50% ﬁbers aligned). When
available, follow-up images were taken and analyzed as well,
following the same criteria.
An appropriate treatment plan for rehabilitation and recovery
was built on an accurate diagnosis and detailed understanding of
the condition to be treated. Treatment areas were deﬁned after
ultrasonography of the injured area (Esaote Alpha diagnostic unit;
Esaote SpA, Genoa, Italy). Finally, the safety of the practitioner,
horse, and equipment were considered at all times because equine
patients were prepared for low-frequency US treatment in such a
way to prevent uncontrolled kicking, distress, or pain (horses were
simply cross-tied to prevent them from turning around). The stress
and/or pain of each subject was estimated during the treatment
Table 1
A detailed overview of the 23 horses included in this EQ Pro study.
Horse No. Weight Breed Gender Age Discipline Limb Diagnosis
1 610 Polish WB G 16 Dressage LH Desmitis MED BR SL
2 580 Hannover G 11 Show jumping RH Desmitis MED BR SL
3 630 Holsteiner G 9 Show jumping RF Desmitis PROX SL
4 630 KWPN G 11 Show jumping RH Desmitis PROX SL
5 580 Oldenburg G 9 Show jumping RF Desmitis LAT BR SL
6 560 Sella IT M 10 Show jumping LF Desmitis MED BR SL
7 500 Thoroughbred F 8 Cross country RF Desmitis PROX SL
8 590 Hannover G 13 Show jumping LH Desmitis PROX SL
9 610 Holsteiner F 14 Show jumping RH Desmitis PROX SL
10 570 Belgian WB G 11 Show jumping LH Desmitis PROX SL
11 590 KWPN G 16 Show jumping LH Desmitis MED BR SL
12 570 Selle FR M 7 Show jumping RH Desmitis LAT BR SL
13 650 Hannover G 12 Dressage LH Desmitis PROX SL
14 380 Quarter Horse S 3 Reining RF Desmitis PROX SL
15 570 Sella IT F 11 Show jumping RF Desmitis LAT BR SL
16 630 Holsteiner F 17 Show jumping RH Desmitis PROX SL
17 570 Thoroughbred F 8 Cross country LF Desmitis PROX SL
18 600 Sella IT G 12 Show jumping LH Desmitis LAT BR SL
19 560 KWPN G 10 Show jumping RF Desmitis PROX SL
20 615 Holsteiner F 7 Show jumping LF Desmitis PROX SL
21 620 Sella IT G 9 Show jumping RF Desmitis PROX SL
22 620 Holsteiner G 12 Dressage RH Desmitis PROX SL
23 590 Holsteiner G 10 Show jumping RH Desmitis PROX SL
Abbreviations: BR, lateral branch; IT, Italiano; LAT, lateral; LF, left front; LH, left hind; MED, medial; RF, right front; RH, right hind; WB, warmblood.
The discipline that the horses were used to is listed, alongside the initial diagnosis, achieved with ultrasound (US).
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backward and or side by side more than four times per minute, (2)
repeated, insisted pawing, and (3) sudden, hasty limb subtraction
were relied on.
2.5. Treatment
The device used for low-frequency US therapeutic treatments
was an EQ Pro (EQ Veterinary, Daytona Beach, Florida; www.
eqveterinary.com). This device produces a low-frequency thera-
peutic US, which operates at 38 kHz (±2 kHz). The unit comes with
six different color-coded transducers, featuring continuous and
pulsed emission and with different transducer shapes to allow
treatment of different musculoskeletal pathologies in different
areas of the horse's body:
 Red transducer (ﬂat headdcontinuous emission) generates
acoustic effects and thermal effects. The red transducer is ideal
to treat large and ﬂat areas and when heat is a desired effect.
 Yellow transducer (concave headdcontinuous emission) gen-
erates acoustic effects and thermal effects. The yellow trans-
ducer is ideal to treat small and rounded areas and when heat is
a desired effect.
 Blue transducer (ﬂat headdpulsed emission) generates acoustic
effects and mechanical vibration. The blue transducer is ideal to
treat large and ﬂat areas and when heat is an undesired effect.
 Green transducer (concave headdpulsed emission) generates
acoustic effects and mechanical vibration. The green transducer
is ideal to treat small and rounded areas and when heat is an
undesired effect.
 Gray transducer (focused convex headdpulsed emission) gen-
erates acoustic effects and mechanical vibration. Because of the
small contact area, US emission is focused. The focused convex
head has a divergent emission.
 White transducer (focused concave headdpulsed emission)
generates acoustic effects and mechanical vibration. Because of
the small contact area, US emission is focused. The focused
concave head has a convergent emission.All transducers induce acoustic effects within targeted tissues.
Continuous emission transducers (red and yellow transducers) are
mainly indicated for chronic conditions and acute muscle condi-
tions or generally speaking when there is the need to increase
vascularization. Continuous emission transducers can also be used
to soften scar tissue.
Pulsed emission transducers (blue and green transducers) are
mainly indicated for acute or subacute conditions or generally
speaking when the user does not want to add heat to an existing
inﬂammation because heat is mostly dissipated by blood circula-
tion. Pulsed emission transducers can also be used to drain edema
and hematoma.
The focused transducers (gray and white transducers) can be
used in acute, subacute, or chronic conditions when very intense
acoustic effects are desired.
EQ Pro allows the user to set the intensity of the power output
and treatment duration. Increasing the intensity of the power
output and the treatment duration allows the user to generate
more intense effects and also to reach deeper targets. The two
advantages of using low-frequency therapeutic US versus high-
frequency US are increased intensity of acoustic effects and depth
of penetration.
EQ Pro therapy does not require treatment areas to be shaved,
only that they are cleaned with water and left wet so as to facilitate
the EQ Pro transduction. US-speciﬁc gel was applied to both the
contact surface of the EQ Pro transducer and directly to the treat-
ment area. This was done so as to further facilitate EQ Pro pene-
tration but also to assist the transducer head to smoothly glide over
the treatment area. Subsequent applications of US gel were made
when it was felt that insufﬁcient gel was present at the treatment
site.
Treatment sessions commenced with the EQ Pro unit set to
its 50% power output setting so that horses could become
accustomed to the EQ Pro therapy. After a minute of treat-
ment at this setting, the power output was then raised to the
desired level. Treatment was performed by massaging the
selected area of the horse while maintaining the US trans-
ducer in direct contact with horse's gel enriched hair. It can
Fig. 1. A comparison of the ultrasound images with the lameness score. (A) Case 10dan 11-y-old Belgian Warmblood show jumping gelding, with a diagnosis of left hind limb acute
proximal suspensory desmitis. (a and b) Diagnostic ultrasound images taken on June 19elameness score 6/10. (b and c) Diagnostic ultrasound images taken on July 23elameness
score 1/10. (B) Case 11da 16-y-old KWPN show jumping gelding, with a diagnosis of left hind limb acute desmitis of the medial branch of the suspensory ligament and chronic
enthesiopathy. (a and b) Diagnostic ultrasound images taken on January 21elameness score 5/10. (b and c) Diagnostic ultrasound images taken on March 12elameness score 3/10.
(C) Case 12da 7-y-old Selle FR show jumping stallion, with a diagnosis of right hind limb subacute desmitis of the lateral branch of the suspensory ligament. (a) A diagnostic
ultrasound image taken on August 5elameness score 4/10. (b) A diagnostic ultrasound image taken on September 23elameness score 0/10. DX, right; LAT, lateral; LAT BR, lateral
branch; MED, medial; MT3, metatarsal bone 3; MT4, metatarsal bone 4; P, posterior hind limb; SX, left.
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gion of the horse to be treated using slight pressure, and
that massage was applied in both circular and linear
directions.2.6. Rehabilitation
The rehabilitation plan adopted throughout this study was
based on the following protocol. For the ﬁrst 4 weeks after
diagnosis, exercise was by walking only (10 minutes twice daily).
From Weeks 4 to 8 after diagnosis, a gradual and increasing ex-
ercise plan of both walking and trotting was adopted up to a
period of 20 minutes. This was also augmented by a gradually
increasing period of canter exercise (1 minute initially and
thereafter an additional minute every third day). This rehabilita-
tion plan was carefully adjusted for each horse depending on the
severity of their injury as well as both clinical and ultrasono-
graphic examinations.3. Results
3.1. General ﬁndings
The summary of the details and diagnosis of the 23 horses
included in this study can be found in Table 1.
It was found that of 23 horses included in this study, 56% had an
injury to their hind-limb, and in 65% of the cases, this was to the
origin of the SL. When the suspensory branches were affected (n ¼
8), the injury was divided evenly between the medial and the
lateral branch.
Evaluation of success was deﬁned by clinical and US examina-
tion to assess resolution of lameness and US improvement. The
outcome of the EQ Pro treatment regimen was found to have a
success rate of 87% as 20 of the 23 horses returned to full compe-
tition status after a period of recovery or rehabilitation training.
Although a clear improvement was found with EQ Pro treatment
for the three remaining horses, they did not improve enough to
return to their chosen sports activity (see Table 2).
Fig. 1. (continued).
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depending on whether the injury was assessed as being acute,
subacute, or chronic. Treatment protocols have been derived from
human physiotherapy protocols and modiﬁed accordingly with the
experience of the authors. All the transducers were applied while
(1) taking care to keep the treatment site covered with gel and (2)
moving the transducer head throughout the treatment.
3.2. Protocol 1dAcute Case
During the ﬁrst week after diagnosis, EQ Pro treatment was
provided 6 days a week using the blue transducer (ﬂat transducerwith pulsed emission) at 70% to 80% of full power for a period of 10
to 15minutes, either once or twice a day (depending on the severity
of the tissues' edema).
During the second week after diagnosis, EQ Pro treatment was
provided 6 days a week using the blue transducer (ﬂat transducer
with pulsed emission) at 80% to 95 % of full power for a period of
6 minutes. Thereafter, the gray transducer (focused convex trans-
ducer with pulsed emission) was used at 80% to 95% of full power
for a period of 5 minutes.
During the third week, and when deemed necessary based on
ultrasonographic and clinical examinations during the fourth week
after diagnosis, EQ Pro treatment was provided three times a week
Fig. 2. A photo showing the application of the EQ Pro transducer head to the region of
treatment.
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sion) at 70% to 85% of full power for a period of 6 minutes. There-
after, the blue transducer (ﬂat transducer with pulsed emission)
was applied at 80% to 95% of full power for a period of 6 minutes.
Then ﬁnally the gray transducer (focused convex transducer with
pulsed emission) was applied at 80% to 95% of full power for a
period of 5 minutes.Table 2
A detailed overview of the 23 horses included in this EQ Pro study.
Horse No. Treatment Protocol Duration (wk) Healthy
1 1 4 6
2 3 3 7
3 2 4 8
4 3 4 8
5 2 3 6
6 1 3 5
7 1 4 4
8 2 3 10
9 1 3 Never
10 1 3 5
11 1 3 Never
12 2 3 4
13 3 4 8
14 1 3 8
15 1 3 8
16 3 4 Never
17 1 3 8
18 2 3 8
19 1 3 10
20 1 3 8
21 2 3 8
22 3 4 4
23 3 4 4
The EQ Pro treatment protocol adopted (see section Materials and Methods and Results fo
of weeks after the initial diagnosis that a healthy ultrasound (US) was recorded for each
competition status is given.3.3. Protocol 2dSubacute Case
During the ﬁrst week after diagnosis, EQ Pro treatment was
provided 6 days a week using the blue transducer (ﬂat transducer
with pulsed emission) at 70% to 80% of full power for a period of 10
to 15 minutes.
During the second week after diagnosis, EQ Pro treatment was
provided three times a week using the blue transducer (ﬂat
transducer with pulsed emission) at 80% to 95% of full power for a
period of 6 minutes. Thereafter, the gray transducer (focused
convex transducer with pulsed emission) was used at 80% to 95% of
full power for a period of 5 minutes.
During the third week, and when deemed necessary based on
ultrasonographic and clinical examinations during the fourth week
after diagnosis, EQ Pro treatment was provided twice a week using
the red transducer (ﬂat transducer with continuous emission) at
70% to 85% of full power for a period of 6 minutes. Thereafter, the
blue transducer (ﬂat transducer with pulsed emission) was applied
at 80% to 95% of full power for a period of 6 minutes. Then ﬁnally
the gray transducer (focused convex transducer with pulsed
emission) was applied at 80% to 95% of full power for a period of
5 minutes.3.4. Protocol 3dChronic Case
During the ﬁrst week after diagnosis, EQ Pro treatment was
provided 6 days a week using the red transducer (ﬂat transducer
with continuous emission) at 70% to 85% of full power for a period
of 6 minutes. Thereafter, the gray transducer (focused convex
transducer with pulsed emission) was applied at 80% to 95% of full
power for a period of 5 minutes.
During the second week after diagnosis, EQ Pro treatment was
provided three times a week using the red transducer (ﬂat trans-
ducer with continuous emission) at 70% to 85 % of full power for a
period of 6 minutes. Thereafter, the blue transducer (ﬂat transducer
with pulsed emission) was used at 80% to 95 % of full power for a
























r details). The number of weeks of EQ Pro treatment are listed as well as the number
horse. Finally, the number of months from the initial diagnosis to a full return to
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of full power for a period of 5 minutes.
During the third week and when deemed necessary based on
ultrasonographic and clinical examinations during the fourth week
after diagnosis, EQ Pro treatment was provided twice a week using
the red transducer (ﬂat transducer with continuous emission) at
70% to 85% of full power for a period of 6 minutes. Thereafter, the
blue transducer (ﬂat transducer with pulsed emission) was used at
80% to 95% of full power for a period of 6 minutes. Then ﬁnally the
gray transducer (focused convex transducer with pulsed emission)
was applied at 80% to 95% of full power for a period of 5 minutes.4. Exemplary Case
4.1. Subject 1 with Clinical History
Case number 1 was a 16-year-old Polish warmblood gelding
used for middle-level dressage competitions. The horse showed left
hindlimb acute 3/5 lameness the day after hard work and an
obvious swelling of the distal plantar aspect of the left metatarsal
region. A diagnostic US examination revealed not only a conspic-
uous bilateral lesion of the SL branches, but an increase in their CSA,
hypoechogenic conﬂuent areas, and moderate periligamentous soft
tissue swelling, as shown in Fig. 3A.
The horse startedwith treatment protocol 1dacute case: for the
ﬁrst 6 days after diagnosis, EQ Pro treatment was given twice a day
on a daily basis using the blue transducer (ﬂat transducer with
pulsed emission) at 80% power output for 10 minutes. During the
second week EQ Pro treatment was given once a day, 6 days aweek,
using the blue transducer (ﬂat transducer with pulsed emission) at
80% power output for 6 minutes, followed by the gray transducer
(focused convex transducer with pulsed emission) at 80% power
output for 5 minutes.
Then in the third and fourth weeks, EQ Pro treatment was given
three times a week. Each treatment session comprised the use of
the red transducer (ﬂat transducer with continuous emission) at
70% power output for 6 minutes, followed by the blue transducer
(ﬂat transducer with pulsed emission) at 80% power output for
6 minutes, and ﬁnally the gray transducer (focused convex trans-
ducer with pulsed emission) was used at 80% power output for
5 minutes.
In the sixth week, a follow-up diagnostic US examination
showed improved echogenicity of the SL branches, a reduction in
their CSA and an almost complete reduction in the periligamentousFig. 3. Case 1: (A) A diagnostic ultrasound image showing a conspicuous bilateral lesion
echogenic conﬂuent areas and moderate periligamentous soft tissue swelling. (B) In the sixt
of the suspensory ligament branches, a reduction in their cross-sectional area and an almothickening, as shown in Fig. 3B. Subsequently, the horse was
managed with a rehabilitation program (see section Materials and
Methods) for a period of 2 months, before resuming regular sport
activity after 4 months, and reinjury was not reported.
For details of the other 22 horses and their treatment period and
outcome, see Table 2.5. Summary of Observations
This study has shown that an EQ treatment duration of 3.3 ±
0.4 weeks on average (minimum 3.0, maximum 4.0, and median
3.0) gave rise to a healthy outcome, as assessed by US after a period
of 6.8 ± 1.9 weeks (minimum 4.0, maximum 10.0, and median 8.0).
The follow-up diagnostic US images for the horses included in this
study showed a clear beneﬁt of EQ Pro treatment with reduced
swelling, and as a consequence, a reduction in the CSA of the
injured region (see Table 3). Indeed, there was a signiﬁcant 15%
decrease (P < .0001) in the CSA of the SLs from 2.71 cm at the time
of diagnosis to 2.30 cm at the time of follow-up. Moreover, there
was found to be an improvement in echogenicity, an indication that
cellular repair had been initiated. In terms of ﬁber alignment, 39% of
the horses presented with a ﬁber alignment of <50% at the time of
diagnosis, but by end of the study at follow-up, only 4% of the
horses had a ﬁber alignment of<50%, and 78% had a ﬁber alignment
of 100%.
Treatment with EQ Pro was followed up with a standard reha-
bilitation program that, on average, lasted for 3.6 ± 1.4 months
(minimum 2.0, maximum 6.0, and median 3.5), with horses
returning to full competition status after a period of 5.3 ±
1.6 months on average (minimum 3.0, maximum 8.0, and median
5.0).
Although this study population is too small to enable statisti-
cally signiﬁcant results, front limb proximal SLs and medial or
lateral branch desmopathy showed a better rate of improvement in
terms of time to return to sport in the opinion of the authors.6. Discussion
To the best of the authors knowledge, this is the ﬁrst study,
albeit a retrospective one, that documents the effects of low-
frequency US on the suspensory system of horses, reporting (1)
the duration of treatment in relation to the severity of the injury
sustained, (2) the point in time at which the injury was deemed toof the suspensory ligament branches, an increase in their cross-sectional area, hypo-
h week, a follow-up diagnostic ultrasound examination showed improved echogenicity
st complete reduction of the periligamentous thickening.
Table 3
A detailed overview of the 23 horses included in this EQ Pro study.
Horse No. Initial CSA (cm) Follow-Up CSA (cm) Initial Fiber Alignment Follow-Up Fiber Alignment Long-Term Follow-Up
1 2.19 1.55 <50% 100% Good
2 2.46 1.69 50% 100% Lost
3 3.72 3.41 50% 100% Lost
4 3.56 3.18 <50% 50% Fair
5 1.51 1.35 50% 100% Good
6 1.91 1.69 50% 100% Lost
7 3.45 2.81 <50% 100% Good
8 2.52 2.21 50% 100% Lost
9 2.51 2.44 <50% 50% Poor
10 4.11 3.52 <50% 100% Good
11 1.55 1.45 50% 50% Poor
12 1.57 1.25 50% 100% Lost
13 4.44 3.21 50% 100% Fair
14 2.96 2.52 <50% 100% Lost
15 2.75 2.12 50% 100% Good
16 2.55 2.48 <50% <50% Poor
17 3.58 3.18 <50% 100% Lost
18 1.55 1.25 50% 100% Good
19 3.21 2.51 50% 100% Lost
20 2.94 2.32 <50% 100% Lost
21 2.57 2.15 50% 100% Lost
22 2.35 2.27 50% 100% Lost
23 2.45 2.33 50% 50% Lost
Abbreviation: CSA, cross-sectional area.
The initial and follow-up CSA as well as ﬁber alignment details are shown. Note that for 3 of the 23 horses, although an improvement in their suspensory ligament injury was
achieved, their recovery was not sufﬁcient to enable a full return to competition status, giving a success rate of 20/23 ¼ 87%.
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competition status.
This study has shown that for the 23 horses examined, 20 were
successfully returned to competition status, and this occurred on
average within a time frame of 21 weeks. Moreover, 20 of the 23
horses were deemed healthy at an US examination after, on
average, 6.8 weeks andwere rehabilitated for, on average,14 weeks.
In a study involving PRP treatment, horses returned to competition
status between 12 and 24 weeks after an acute proximal suspen-
sory ligament desmitis [15]. However, PRP resulted in horses
returning to exercise ﬁrst after a period of 14.5 weeks on average
[15], compared to the 6.8 weeks reported in the present study. Stem
cell treatment has also been applied to proximal suspensory liga-
ment desmitis, with a report of a return to preinjury performance
status 32 weeks after the start of regenerative treatment [16],
compared with the average time frame of 21 weeks in the present
low-frequency US study.
One of the problems associated with repair of ligaments is that
often rather more collagen III is laid down in the newly developing
matrix [17]. Ligaments and tendons are arranged as long, thin
collagenous ﬁbers (collagen I) with an inherent characteristic
waviness also known as crimp [6]. Collagen III ﬁbers are rather
smaller and less elastic than collagen I ﬁbers [18]. During remod-
eling, the collagen ﬁbers become aligned in the direction of the
dominant stress, and the collagen III ﬁbers are replaced with
collagen I ﬁbers [19]. However, in many cases, the repaired tissue
remains biochemically and ultrastructurally abnormal, even up to a
year after injury, and does not completely regain the biomechanical
properties it possessed initially [20].
It has been stated that the degree of ultrasonographic ab-
normality usually reﬂects the severity of the lameness [5]. This
study has been able to conﬁrm this, as the US images and their
severity matched with very close approximation, the degree of
lameness noted for the 23 cases described. As it can be
deduced from Table 3, CSA and ﬁber alignment patterns
improved after treatment with the EQ Pro, and matched the
clinical improvements noted in terms of the original degree of
lameness.Low-frequency US is a new and novel technique that does not
require sedation of horses during treatment. It is also a very easy
technique to use and can not only be performed in a routine Vet-
erinary Clinic or ﬁeld setting but is very well tolerated by horses. As
a technique, it is known to produce cavitation [21]. Indeed, the use
of cavitation for histotripsy is well known, particularly as a means
of treating prostate diseases, liver cancer, kidney stones, and
thrombolysis [21]. However, low-frequency US has been shown to
have other effects besides those of tissue ablation. In a very recent
article, Wu et al [22] were able to show that low-frequency US
enhances and induces autophagy. These authors were able to
document that low-frequency US induces cavitation in tissue, pri-
marily affecting the endoplasmic reticulum and resulting in stress
(referred to as endoplasmic reticulum stress [ERs]) [22]. ERs is
known to caused impaired function of the endoplasmic reticulum,
leading to accumulation of misfolded and unfolded proteins [23]. Of
particular interest is the observation that low-frequency-induced
ERs signiﬁcantly increase autophagy levels within targeted
tissues [22].
Autophagy is a dynamic multistep process in which essential
autophagy genes participate in forming double-membrane struc-
tures that engulf damaged cellular proteins, lipids, and organelles
before delivering them to lysosomes for subsequent degradation
[24e26]. Under normal physiological conditions, autophagic ac-
tivity is low, but it can be induced in response to a variety of stimuli,
including nutrient limitation, oxidative stress, hypoxia, increased
metabolic demands, ERs, physiological agents, and inﬂammation
[27]. In this way, autophagy contributes to cellular homeostasis by
removing damaged organelles and maintaining their normal
turnover [28].
Beside the direct activation of repair processes, cavitation bub-
bles also generate an effect called microstreaming [29]. The effects
of therapeutic US in this way (diathermy, acoustical streaming, and
microstreaming) are well known and documented [29,30]. Indeed
it is known that different transducers can be used to induce speciﬁc
conditions; for example, diathermy to revascularize chronic con-
ditions and acoustical streaming and microstreaming to facilitate
the drainage of edema [31e34].
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and overuseevery often in young and physically active subjects
[35,36]. This most commonly arises because of that rapid devel-
opment of muscle tissue under training, giving rise to extremely
rapid and high levels of force without being compensated by
equally rapid changes in the ligaments and tendons [37,38].
Although adaptation of tendons has been demonstrated [39,40],
this adaption is slower than the development of a strong muscle
during periods of regular training exercise, with rapid increases in
force production resulting in ligament and tendon damage at a
structural level [41]. A number of systemic diseases are also known
to be associated with general defects in matrix metabolism and
structure that compromise ligament and tendon strength and
elasticity, moreover the term “spontaneous tendon rupture” is
being used on a more regular basis in connection with sport [42].
A few animal studies have been performed using an overuse
protocol [43e45], where rats ran with a velocity of 17 m/min, 5 d/
wk, 1 hr/d, either uphill or downhill for a period of between 2 and
16 weeks. In such experiments, a decreased collagen ﬁber organi-
zation and increased number of cell nuclei was observed [46,47].
Yet, exactly how the connective tissue of the ligaments and tendons
manages the active tension transfer from bone to bone or muscle to
bone, respectively, and whether this tension transfer is affected by
inﬂammation, remains unclear.
7. Conclusion
This study describes a physiotherapy treatment approach based
on the use of low-frequency US, in connection with a rehabilitation
program that is tailored to each single case, and one that takes into
account the age, discipline, type of lesion, previous treatment, and
response to treatment. It is shown that EQ Pro treatment requires
on average a period of 3.3 ± 0.4 weeks to result in a successful
outcome (return to full competition status) for 87% of the 23 horses
included in this study. It is furthermore quick and easy to use in the
Equine Veterinary Clinic setting and does not require sedation.
There is now a need for more detailed studies into the mechanisms
by which low-frequency US is able to activate autophagy, as well as
the role of autophagy in the healing process of the SLs of injured
horses.
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